Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 10/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781558 | 0.91 | PIK3CA (0.46) | FYNPIK3CAMTORKCNH2CLK1 | |
| SCHEMBL24460245 | 0.90 | PIK3CA (0.42) | FYNPIK3CAMTORKCNH2FLT3 | |
| SCHEMBL24460273 | 0.86 | FYN (0.43) | FYNBCL2MDM2MCL1FLT3 | |
| SCHEMBL24460237 | 0.86 | PIK3CA (0.48) | PIK3CAMTORKCNH2CLK1DYRK1A | |
| SCHEMBL29652169 | 0.86 | PIK3CA (0.42) | FYNPIK3CAMTORKCNH2CLK1 | |
| SCHEMBL24460314 | 0.86 | PIK3CA (0.42) | FYNPIK3CAMTORKCNH2CLK1 | |
| SCHEMBL24460204 | 0.85 | FYN (0.54) | FYNPIK3CAMTORKCNH2CLK1 | |
| SCHEMBL24460238 | 0.83 | PIK3CA (0.43) | PIK3CAMTORKCNH2CLK1DYRK1A | |
| SCHEMBL24460243 | 0.82 | PIK3CA (0.42) | PIK3CAMTORKCNH2CLK1DYRK1A | |
| SCHEMBL24460291 | 0.81 | PIK3CA (0.46) | PIK3CAMTORKCNH2CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | FYN 1748/4885PIK3CA 1740/4885MTOR 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.